| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Mu-type opioid receptor |
|---|
| Ligand | BDBM50277101 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_540509 (CHEMBL1030613) |
|---|
| EC50 | 9.8±n/a nM |
|---|
| Citation |  Wentland, MP; Lu, Q; Ganorkar, R; Zhang, SZ; Jo, S; Cohen, DJ; Bidlack, JM Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine. Bioorg Med Chem Lett19:365-8 (2008) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Mu-type opioid receptor |
|---|
| Name: | Mu-type opioid receptor |
|---|
| Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 44789.51 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P35372 |
|---|
| Residue: | 400 |
|---|
| Sequence: | MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
|
|
|
|---|
| BDBM50277101 |
|---|
| n/a |
|---|
| Name | BDBM50277101 |
|---|
| Synonyms: | (1S,16R)-13-(cyclopropylmethyl)-1,16-dimethyl-5,7,13-triazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2,4(8),6,9-tetraene | CHEMBL518712 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C19H25N3 |
|---|
| Mol. Mass. | 295.4219 |
|---|
| SMILES | C[C@H]1C2Cc3cc4[nH]cnc4cc3[C@@]1(C)CCN2CC1CC1 |r,TLB:11:12:1:17.16.15,18:17:1:4.12.3| |
|---|
| Structure | 
|
|---|
Search and Browse
